AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma (NYSE: AEON) has announced the approval of inducement awards in connection with Rob Bancroft's appointment as President and Chief Executive Officer. The Company's Compensation Committee has approved two key grants:
1. A non-qualified stock option to purchase 59,034 shares of AEON Class A common stock, with an exercise price matching the closing price on the grant date
2. 177,103 restricted stock units (RSUs) to be granted upon Form S-8 registration filing or employment start date
Both awards will vest over a four-year period, with 25% vesting annually from the employment start date. These grants are being made under AEON's 2025 Employment Inducement Incentive Award Plan and comply with Section 711 of NYSE American Company Guide.
AEON Biopharma (NYSE: AEON) ha annunciato l'approvazione di premi di incentivo in relazione alla nomina di Rob Bancroft come Presidente e Amministratore Delegato. Il Comitato per la Remunerazione della Società ha approvato due assegnazioni principali:
1. Un'opzione azionaria non qualificata per acquistare 59.034 azioni di azioni ordinarie di Classe A di AEON, con un prezzo di esercizio pari al prezzo di chiusura del giorno della concessione.
2. 177.103 unità di azioni vincolate (RSU) da assegnare al momento della presentazione della registrazione sul Modulo S-8 o alla data di inizio del rapporto di lavoro.
Entrambi i premi matureranno in un periodo di quattro anni, con il 25% che matura annualmente a partire dalla data di inizio del lavoro. Queste assegnazioni sono effettuate nell'ambito del Piano di Incentivi per l'Assunzione 2025 di AEON e sono conformi alla Sezione 711 della Guida della NYSE American Company.
AEON Biopharma (NYSE: AEON) ha anunciado la aprobación de premios de incentivo relacionados con el nombramiento de Rob Bancroft como Presidente y Director Ejecutivo. El Comité de Compensación de la Compañía ha aprobado dos concesiones clave:
1. Una opción sobre acciones no calificada para comprar 59,034 acciones de acciones comunes Clase A de AEON, con un precio de ejercicio igual al precio de cierre en la fecha de concesión.
2. 177,103 unidades de acciones restringidas (RSU) que se otorgarán al presentar el formulario S-8 o en la fecha de inicio del empleo.
Ambos premios se consolidarán en un período de cuatro años, con un 25% consolidándose anualmente desde la fecha de inicio del empleo. Estas concesiones se realizan bajo el Plan de Incentivos por Contratación 2025 de AEON y cumplen con la Sección 711 de la Guía de Empresas NYSE American.
AEON Biopharma (NYSE: AEON)는 Rob Bancroft의 사장 겸 최고경영자(CEO) 임명과 관련된 유인 보상 승인 소식을 발표했습니다. 회사 보상 위원회는 두 가지 주요 보상안을 승인했습니다:
1. 부여일 종가와 동일한 행사가격으로 AEON 클래스 A 보통주 59,034주를 매수할 수 있는 비자격 스톡 옵션
2. S-8 등록서 제출 시점 또는 고용 시작일에 부여되는 177,103개의 제한 주식 단위(RSU)
두 보상안 모두 4년 기간에 걸쳐 베스팅되며, 고용 시작일부터 매년 25%씩 베스팅됩니다. 이 보상은 AEON의 2025년 고용 유인 인센티브 보상 계획에 따라 이루어지며, NYSE American 회사 가이드 섹션 711을 준수합니다.
AEON Biopharma (NYSE : AEON) a annoncé l'approbation des récompenses d'incitation liées à la nomination de Rob Bancroft en tant que Président et Directeur Général. Le comité de rémunération de la société a approuvé deux attributions clés :
1. Une option d'achat d'actions non qualifiée pour acquérir 59 034 actions ordinaires de classe A d'AEON, avec un prix d'exercice égal au cours de clôture à la date d'attribution.
2. 177 103 unités d'actions restreintes (RSU) à attribuer lors du dépôt du formulaire S-8 ou à la date de début d'emploi.
Les deux récompenses seront acquises sur une période de quatre ans, avec 25 % acquises chaque année à partir de la date de début d'emploi. Ces attributions sont effectuées dans le cadre du Plan d'Incitation à l'Embauche 2025 d'AEON et sont conformes à la Section 711 du Guide des Sociétés NYSE American.
AEON Biopharma (NYSE: AEON) hat die Genehmigung von Anreizprämien im Zusammenhang mit der Ernennung von Rob Bancroft zum Präsidenten und CEO bekannt gegeben. Das Vergütungskomitee des Unternehmens hat zwei wichtige Zuteilungen genehmigt:
1. Eine nicht qualifizierte Aktienoption zum Kauf von 59.034 Aktien der AEON Class A Stammaktien, mit einem Ausübungspreis, der dem Schlusskurs am Zuteilungsdatum entspricht.
2. 177.103 Restricted Stock Units (RSUs), die bei Einreichung der Registrierung auf Formular S-8 oder zum Beschäftigungsbeginn gewährt werden.
Beide Prämien werden über einen Zeitraum von vier Jahren unverfallbar, wobei jährlich 25 % ab dem Beschäftigungsbeginn unverfallbar werden. Diese Zuteilungen erfolgen im Rahmen des AEON 2025 Employment Inducement Incentive Award Plans und entsprechen Abschnitt 711 des NYSE American Company Guide.
- Successful recruitment of new President and CEO indicating strategic leadership transition
- Structured compensation package aligning executive interests with long-term shareholder value
- Potential shareholder dilution from new equity grants
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company’s Compensation Committee of the Board of Directors has approved the grant of inducement awards.
The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the granting of equity awards to new employees of the Company. The stock option will be granted on Mr. Bancroft’s employment start date and will have an exercise price equal to the closing price of AEON’s Class A common stock on the NYSE American on the grant date. In addition, the Compensation Committee approved the grant to Mr. Bancroft of 177,103 restricted stock units (“RSUs”) under the Inducement Plan. The RSUs will be granted on the later of (i) the date on which the Company files a Form S-8 registration statement with respect to the Inducement Plan and (ii) Mr. Bancroft’s employment start date.
The stock option and RSUs vest over four years,
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
What compensation package did AEON Biopharma offer to new CEO Rob Bancroft?
How are AEON Biopharma's inducement grants structured for the new CEO?
When will AEON Biopharma's new CEO receive his RSU grant?
What is the exercise price for AEON's stock options granted to the new CEO?
